Arch Biopartners Inc. (ACHFF)
USD 1.1
(-7.56%)
USD 1.1
(-7.56%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 6.68 Million CAD | 31.2% |
| 2022 | 5.09 Million CAD | -22.26% |
| 2021 | 6.55 Million CAD | 42.12% |
| 2020 | 4.6 Million CAD | 32.85% |
| 2019 | 3.46 Million CAD | 101.91% |
| 2018 | 1.71 Million CAD | 172.19% |
| 2017 | 631.34 Thousand CAD | 30.46% |
| 2016 | 483.94 Thousand CAD | -4.74% |
| 2015 | 508.02 Thousand CAD | 23.19% |
| 2014 | 412.37 Thousand CAD | -10.78% |
| 2013 | 462.19 Thousand CAD | 2.89% |
| 2012 | 449.23 Thousand CAD | 13.15% |
| 2011 | 397.02 Thousand CAD | 7.18% |
| 2010 | 370.41 Thousand CAD | 6.58% |
| 2009 | 347.55 Thousand CAD | -86.49% |
| 2008 | 2.57 Million CAD | 30.33% |
| 2007 | 1.97 Million CAD | 23.52% |
| 2006 | 1.59 Million CAD | -21.86% |
| 2005 | 2.04 Million CAD | 1.47% |
| 2004 | 2.01 Million CAD | 28.74% |
| 2003 | 1.56 Million CAD | 3619.39% |
| 2002 | 42.08 Thousand CAD | -81.7% |
| 2001 | 229.98 Thousand CAD | -28.18% |
| 2000 | 320.2 Thousand CAD | 56.02% |
| 1999 | 205.23 Thousand CAD | -35.03% |
| 1998 | 315.9 Thousand CAD | -16.91% |
| 1997 | 380.17 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 8.22 Million CAD | 29.53% |
| 2024 Q3 | 8.09 Million CAD | -1.56% |
| 2024 Q1 | 6.34 Million CAD | -4.96% |
| 2023 FY | 6.68 Million CAD | 31.2% |
| 2023 Q4 | 6.68 Million CAD | -6.83% |
| 2023 Q1 | 5.18 Million CAD | 1.86% |
| 2023 Q3 | 7.17 Million CAD | -21.41% |
| 2023 Q2 | 9.12 Million CAD | 75.91% |
| 2022 Q1 | 5.55 Million CAD | -15.13% |
| 2022 FY | 5.09 Million CAD | -22.26% |
| 2022 Q4 | 5.09 Million CAD | -12.51% |
| 2022 Q2 | 5.91 Million CAD | 6.35% |
| 2022 Q3 | 5.82 Million CAD | -1.55% |
| 2021 Q2 | 6.07 Million CAD | 9.84% |
| 2021 Q3 | 7.52 Million CAD | 23.77% |
| 2021 Q4 | 6.55 Million CAD | -12.91% |
| 2021 FY | 6.55 Million CAD | 42.12% |
| 2021 Q1 | 5.53 Million CAD | 20.04% |
| 2020 Q3 | 4.41 Million CAD | 9.17% |
| 2020 Q4 | 4.6 Million CAD | 4.39% |
| 2020 FY | 4.6 Million CAD | 32.85% |
| 2020 Q2 | 4.04 Million CAD | 12.13% |
| 2020 Q1 | 3.6 Million CAD | 3.95% |
| 2019 Q2 | 2.42 Million CAD | 10.22% |
| 2019 Q1 | 2.2 Million CAD | 28.13% |
| 2019 Q3 | 3.23 Million CAD | 33.31% |
| 2019 Q4 | 3.46 Million CAD | 7.25% |
| 2019 FY | 3.46 Million CAD | 101.91% |
| 2018 Q3 | 1.66 Million CAD | 1.43% |
| 2018 FY | 1.71 Million CAD | 172.19% |
| 2018 Q4 | 1.71 Million CAD | 3.44% |
| 2018 Q2 | 1.63 Million CAD | 45.51% |
| 2018 Q1 | 1.12 Million CAD | 78.29% |
| 2017 Q4 | 631.34 Thousand CAD | 12.33% |
| 2017 FY | 631.34 Thousand CAD | 30.46% |
| 2017 Q1 | 577.61 Thousand CAD | 19.36% |
| 2017 Q2 | 546.88 Thousand CAD | -5.32% |
| 2017 Q3 | 562.03 Thousand CAD | 2.77% |
| 2016 FY | 483.94 Thousand CAD | -4.74% |
| 2016 Q4 | 483.94 Thousand CAD | -2.09% |
| 2016 Q2 | 491.06 Thousand CAD | 4.53% |
| 2016 Q1 | 469.79 Thousand CAD | -7.53% |
| 2016 Q3 | 494.25 Thousand CAD | 0.65% |
| 2015 Q2 | 415.96 Thousand CAD | -9.31% |
| 2015 Q1 | 458.64 Thousand CAD | 11.22% |
| 2015 Q4 | 508.02 Thousand CAD | 23.43% |
| 2015 FY | 508.02 Thousand CAD | 23.19% |
| 2015 Q3 | 411.57 Thousand CAD | -1.05% |
| 2014 FY | 412.37 Thousand CAD | -10.78% |
| 2014 Q4 | 412.37 Thousand CAD | -14.82% |
| 2014 Q3 | 484.11 Thousand CAD | 8.38% |
| 2014 Q1 | 517.07 Thousand CAD | 11.87% |
| 2014 Q2 | 446.66 Thousand CAD | -13.62% |
| 2013 Q3 | 478.26 Thousand CAD | 3.06% |
| 2013 Q4 | 462.19 Thousand CAD | -3.36% |
| 2013 Q1 | 424.75 Thousand CAD | -5.45% |
| 2013 Q2 | 464.06 Thousand CAD | 9.25% |
| 2013 FY | 462.19 Thousand CAD | 2.89% |
| 2012 Q4 | 449.23 Thousand CAD | 7.58% |
| 2012 Q1 | 411.43 Thousand CAD | 3.63% |
| 2012 Q2 | 426.28 Thousand CAD | 3.61% |
| 2012 Q3 | 417.57 Thousand CAD | -2.04% |
| 2012 FY | 449.23 Thousand CAD | 13.15% |
| 2011 FY | 397.02 Thousand CAD | 7.18% |
| 2011 Q4 | 397.02 Thousand CAD | 0.12% |
| 2011 Q3 | 396.56 Thousand CAD | -0.05% |
| 2011 Q2 | 396.77 Thousand CAD | -8.38% |
| 2011 Q1 | 433.03 Thousand CAD | 16.91% |
| 2010 Q2 | 370.09 Thousand CAD | 6.48% |
| 2010 FY | 370.41 Thousand CAD | 6.58% |
| 2010 Q1 | 347.55 Thousand CAD | 34.25% |
| 2010 Q3 | 426.17 Thousand CAD | 15.15% |
| 2010 Q4 | 370.41 Thousand CAD | -13.08% |
| 2009 Q4 | 258.89 Thousand CAD | 11.77% |
| 2009 FY | 347.55 Thousand CAD | -86.49% |
| 2009 Q1 | 2.57 Million CAD | -38.04% |
| 2009 Q2 | 2.06 Million CAD | -19.55% |
| 2009 Q3 | 231.62 Thousand CAD | -88.81% |
| 2008 Q4 | 4.15 Million CAD | 40.04% |
| 2008 Q1 | 1.97 Million CAD | -4.03% |
| 2008 Q2 | 2.67 Million CAD | 35.56% |
| 2008 FY | 2.57 Million CAD | 30.33% |
| 2008 Q3 | 2.96 Million CAD | 10.81% |
| 2007 FY | 1.97 Million CAD | 23.52% |
| 2007 Q4 | 2.05 Million CAD | 35.51% |
| 2007 Q3 | 1.51 Million CAD | -2.43% |
| 2007 Q2 | 1.55 Million CAD | -2.65% |
| 2007 Q1 | 1.59 Million CAD | -2.06% |
| 2006 FY | 1.59 Million CAD | -21.86% |
| 2006 Q4 | 1.63 Million CAD | 1.94% |
| 2006 Q3 | 1.6 Million CAD | -0.17% |
| 2006 Q2 | 1.6 Million CAD | -21.59% |
| 2006 Q1 | 2.04 Million CAD | 9.49% |
| 2005 Q4 | 1.86 Million CAD | 4.65% |
| 2005 Q2 | 1.84 Million CAD | -8.39% |
| 2005 Q1 | 2.01 Million CAD | -11.02% |
| 2005 FY | 2.04 Million CAD | 1.47% |
| 2005 Q3 | 1.78 Million CAD | -3.33% |
| 2004 Q2 | 1.43 Million CAD | -8.48% |
| 2004 Q1 | 1.56 Million CAD | 933.26% |
| 2004 FY | 2.01 Million CAD | 28.74% |
| 2004 Q4 | 2.26 Million CAD | 21.08% |
| 2004 Q3 | 1.87 Million CAD | 30.57% |
| 2003 Q4 | 151.48 Thousand CAD | 94.57% |
| 2003 FY | 1.56 Million CAD | 3619.39% |
| 2003 Q1 | 42.08 Thousand CAD | -75.12% |
| 2003 Q2 | 123.06 Thousand CAD | 192.42% |
| 2003 Q3 | 77.85 Thousand CAD | -36.73% |
| 2002 Q1 | 229.98 Thousand CAD | 0.0% |
| 2002 Q4 | 169.15 Thousand CAD | 7.74% |
| 2002 FY | 42.08 Thousand CAD | -81.7% |
| 2002 Q3 | 157 Thousand CAD | 63.16% |
| 2002 Q2 | 96.23 Thousand CAD | -58.16% |
| 2001 Q2 | 303.57 Thousand CAD | -5.19% |
| 2001 Q3 | 301.06 Thousand CAD | -0.83% |
| 2001 FY | 229.98 Thousand CAD | -28.18% |
| 2001 Q1 | 320.2 Thousand CAD | 0.0% |
| 2000 Q1 | 205.23 Thousand CAD | 0.0% |
| 2000 FY | 320.2 Thousand CAD | 56.02% |
| 1999 FY | 205.23 Thousand CAD | -35.03% |
| 1999 Q1 | 315.9 Thousand CAD | -14.59% |
| 1998 Q3 | 340.46 Thousand CAD | -6.43% |
| 1998 Q2 | 363.85 Thousand CAD | 0.0% |
| 1998 FY | 315.9 Thousand CAD | -16.91% |
| 1998 Q4 | 369.85 Thousand CAD | 8.63% |
| 1997 FY | 380.17 Thousand CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 87.466% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 30.276% |
| SQZ Biotechnologies Company | 50.03 Million USD | 86.648% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 90.781% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 88.679% |
| Mesoblast Limited | 188.44 Million USD | 96.455% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -73.468% |
| Genus plc | 485 Million USD | 98.622% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -14.349% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -165.506% |
| Marizyme, Inc. | 26.67 Million USD | 74.955% |
| ContraFect Corporation | 32.53 Million USD | 79.463% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -75.816% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -237.201% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -74.546% |
| Intellipharmaceutics International Inc. | 12 Million USD | 44.366% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 43.277% |
| MultiCell Technologies, Inc. | 1617.67 USD | -412900.859% |
| Accustem Sciences Inc. | 1.07 Million USD | -519.046% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 91.37% |
| EV Biologics, Inc. | 2.11 Million USD | -215.876% |
| Q BioMed Inc. | 8.13 Million USD | 17.853% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 91.944% |
| Neon Bloom, Inc. | 1.22 Million USD | -444.848% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -29.828% |
| Biomind Labs Inc. | 1.49 Million USD | -345.812% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 97.263% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 63.697% |
| Skye Bioscience, Inc. | 14.07 Million USD | 52.524% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -232.366% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -4601.778% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 29.421% |
| IMV Inc. | 37.93 Million USD | 82.387% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -3221.959% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -16.276% |
| GB Sciences, Inc. | 5.41 Million USD | -23.321% |
| Alpha Cognition Inc. | 7.16 Million USD | 6.752% |
| HST Global, Inc. | 593.59 Thousand USD | -1025.517% |
| CSL Limited | 18.62 Billion USD | 99.964% |
| Halberd Corporation | 728.71 Thousand USD | -816.813% |
| Enzolytics Inc. | 365.26 Million USD | 98.171% |
| Resverlogix Corp. | 67.39 Million USD | 90.087% |
| Affymax, Inc. | 8.87 Million USD | 24.687% |
| SYBLEU INC | 681.41 Thousand USD | -880.461% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -696.558% |
| argenx SE | 444.95 Million USD | 98.498% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 91.083% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -289.789% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 43.872% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -82.284% |
| AVAX Technologies, Inc. | 3.99 Million USD | -67.286% |
| Zenith Capital Corp. | 27.56 Thousand USD | -24133.708% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.496% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -2699.446% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -78.909% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -881.295% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 94.373% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 26.113% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -9882.207% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -365.944% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 86.708% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -146.382% |
| BioStem Technologies, Inc. | 15.9 Million USD | 57.994% |
| ONE Bio Corp. | 27.49 Million USD | 75.702% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -1337.703% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -24253.848% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -430.577% |
| Agentix Corp. | 2.51 Million USD | -166.116% |
| LadRx Corporation | 2.2 Million USD | -203.609% |
| Cell Source, Inc. | 15.8 Million USD | 57.733% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -14847.626% |
| Regen BioPharma, Inc. | 5.45 Million USD | -22.416% |
| Regen BioPharma, Inc. | 5.45 Million USD | -22.416% |
| NovAccess Global Inc. | 7.86 Million USD | 15.008% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 73.002% |
| Itoco Inc. | 1.65 Million USD | -304.137% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -225.653% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -10.448% |
| Kadimastem Ltd | 3.5 Million USD | -90.62% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -1484.796% |
| CytoDyn Inc. | 127.89 Million USD | 94.776% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -15883.614% |
| Mobile Lads Corp. | 1.31 Million USD | -408.642% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -326.525% |
| Qrons Inc. | 1.48 Million USD | -348.776% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 39.513% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -726.044% |
| Rebus Holdings, Inc. | 5.24 Million USD | -27.451% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -9.49% |
| International Stem Cell Corporation | 5.27 Million USD | -26.606% |
| Bioxytran, Inc. | 3.24 Million USD | -105.601% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -967.577% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -44.7% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 83.703% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 69.993% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -229.862% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -21.96% |
| Neutra Corp. | 973.52 Thousand USD | -586.265% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 76.974% |
| PureTech Health plc | 125.58 Million USD | 94.68% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -77.822% |
| IXICO plc | 1.9 Million USD | -251.577% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 67.456% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 93.534% |
| CSL Limited | 18.62 Billion USD | 99.964% |
| Cellectis S.A. | 249.36 Million USD | 97.321% |